88 results about "Receptor targeting" patented technology

CD44, the receptor for hyaluronic acid, has complex functions in cellular physiology, cell migration and tumour metastasis. The inventors have previously found that human CD44 receptor overexpression in mouse fibrosarcoma cells inhibits subcutaneous tumour growth in mice [Kogerman et al., Oncogene 1997; 15:1407-16; Kogerman et al., Clin Exp Metastasis 1998; 16:83-93]. Here it is demonstrated that a tumour growth inhibitory effect of CD44 is caused by block of angiogenesis. Furthermore, the inventors have found that soluble recombinant CD44 hyaluronic acid binding domain (CD44HABD) inhibits angiogenesis in vivo in cLick and mouse and thereby inhibits human tumour growth of various origins. The anti-angiogenic effect of CD44-HABD is independent of hyaluronic acid (HA) binding, since non-HA-binding mutants of CD44HABD still maintain anti-angiogenic properties. The invention discloses soluble CD44 recombinant proteins as a novel class of angiogenesis inhibitors based on targeting of vascular cell surface receptor. A method of block of angiogenesis and treatment of human tumours using recombinant CD44 proteins as well as their analogues is disclosed. As a further embodiment of the invention, methods for screening for new drug targets using CD44 recombinant proteins and their analogues is presented.

The present invention provides a single-chain antibody targeting CD317, the single-chain antibody targeting CD317 comprises an amino acid sequence shown in SEQ ID NO: 1, and the single-chain antibodytargeting CD317 is a humanized single-chain antibody. The present invention also provides a chimeric antigen receptor T cell comprising the single-chain antibody targeting CD317, wherein the chimericantigen receptor targeting CD317 can specifically target CD317, the expansion of T cells in patients is promoted, the tumor cells can be efficiently and specifically killed, and damage is hardly generated on the normal cells. In addition, the chimeric antigen receptor T cell targeting CD317 produced by humanized single-chain antibody can keep the ability of self-renewal and tumour lethality. The invention also provides a preparation method and an application of the chimeric antigen receptor T cell targeting CD317.

Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.

The invention relates to the technical field of radiopharmaceutical chemistry, and particularly relates to a programmed cell death protein receptor-1 targeted molecular probe and a preparation methodand application thereof. According to the programmed cell death protein receptor-1 targeted molecular probe, the small-molecule probe has medium affinity to target PD-L1, can be selectively taken in aPD-L1 positive tumor site, can well distinguish negative and positive tumors, has response to a PD-L1 high-expression tumor site, and can be used for developing a PD-L1 small-molecule PET developer.

The invention discloses a preparation method of a polysaccharide grafted folic acid copolymer and a nanoparticle thereof. The method includes: using anhydrous dimethylsulfoxide to dissolve folic acid,then adding 1-hydroxybenzotriazole and N-N'-dicyclohexylcarbodiimide for carboxyl activating reaction, mixing a carboxyl activated folic acid solution with a dimethylsulfoxide solution of polysaccharide, carrying out esterification reaction for 24-72h under nitrogen protection and at a temperature of 40-80DEG C, and performing purification to obtain a copolymer mixture; conducting freezing dryingto obtain the polysaccharide grafted folic acid copolymer lyophilized powder, i.e. the polysaccharide grafted folic acid copolymer. The polysaccharide grafted folic acid copolymer can be applied as acarrier in preparation of a nanoparticle preparation with folic acid receptor targeting function, and the nanoparticle preparation can be used for tumor targeted drug delivery.

The invention provides a pH (potential of hydrogen) controlled-release targeted medicine nanometer delivery carrier, a method for preparing the same and application of the pH controlled-release targeted medicine nanometer delivery carrier. Fe3O4 is used as a core for the pH controlled-release targeted medicine nanometer delivery carrier, mSiO2 is used as a shell for the pH controlled-release targeted medicine nanometer delivery carrier, -NH2 is modified on the surface of Fe3O4@mSiO2, a targeted receptor folic acid (FA) and immobilized daunomycin (DNM) are linked up on the surface of the Fe3O4@mSiO2 by means of amide reaction, blocking is ultimately carried out by the aid of CaCO3, pH value response controlled release can be implemented, 'zero-release' effects can be realized in blood circulation, and accordingly toxic and side effects of medicines on human bodies can be reduced. The pH controlled-release targeted medicine nanometer delivery carrier, the method and the application havethe advantages that the pH controlled-release targeted medicine nanometer delivery carrier is combined with the mSiO2 which is excellent in biocompatibility and high in specific surface area and has surfaces easy to modify and wrap Fe3O4 nanometer micro-spheres, modification is carried out by the aid of amine (the -NH2), then the targeted receptor folic acid is grafted, and accordingly the anticancer performance of the targeted medicines can be improved by the aid of multi-targeting generated by magnetic targeting and receptor targeting and is obviously superior to single targeting; the performance of targeted medicine controlled-release systems can be improved by the aid of the physiological pH stability of calcium carbonate.

The invention relates to a GPC3 (glypican-3) receptor targeted polypeptide radioactive diagnosis or therapeutic drug. The GPC3 receptor targeted polypeptide radioactive diagnosis or therapeutic drug includes: polypeptide with an amino acid sequence shown as SEQ ID NO:1; and a radionuclide or positron-emitting nuclide marker coupled to the polypeptide. The invention adopts the radionuclide labeled polypeptide as a hepatocellular carcinoma specific targeting molecular probe to show the expression situation of the GPC3 receptor in hepatocellular carcinoma tumor tissue on a living body level, and improves the effective rate of hepatocellular carcinoma oncotherapy. For lung cancer, melanoma and other GPC3 receptor-positive tumors, the GPC3 receptor targeted polypeptide can also be used for preparation of drugs for diagnosis or treatment of lung cancer and melanoma.

The invention relates to a chemical gene drug co-loaded targeted nano drug delivery system and a preparation method thereof, and in particular relates to a tumor microenvironment hyaluronidase triggered allosteric-charge turnover type chemical/gene drug co-loaded targeted nano drug delivery system and a preparation method thereof. The nano drug delivery system is characterized by being co-assembled by co-loading chemical and gene drugs through a polystyrene-polydimethylbiguanide (PMet) cationic polymer by adopting hyaluronic acid-sulfydryl (HA-SH) with CD44 receptor targeting and tumor microenvironment hyaluronidase (HAase) sensitivity through electrostatic bonding and mercaptan chemical crosslinking. According to the invention, low-toxicity, targeted and efficient treatment of tumors be realized, and a novel multifunctional nano-carrier for treating tumors based on a chemical combined gene drug and a preparation application strategy are provided for anti-tumor research.

The present invention discloses a Plectin-1 receptor targeting novel cationic KTLLPTPK-lipopeptide. The present invention further discloses a liposomal formulation comprising the cationic KTLLPTPK-lipopeptide, at least two co-lipids, therapeutic agents and a pharmaceutically acceptable carrier. The present invention also provides a method for regressing established pancreatic tumors comprising administering therapeutically effective amount of the liposomal formulation with the therapeutic agents in combination with targeted genetic immunization (DNA vaccination) i.e. by immunizing mice with electrostatic complexes (direct in-vivo DC-targeting cationic liposomes) of DNA vaccines encoding mesothelin (p-CMV-MSLN).

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure:

wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

The invention relates to a NK1 receptor-targeting antagonist and application of the same to chemotherapy-induced nausea and vomiting, belonging to the technical field of adjuvant therapeutics for tumor chemotherapy. The invention provides a compound as shown in a formula I which is described in the specification, or a racemate, stereoisomer, tautomer, isotopic label, oxynitride or pharmaceutically-acceptable salt thereof. The invention also provides a preparation method for the compound, a pharmaceutical compositions and the application of the compound or the racemate, stereoisomer, tautomer,isotopic label, oxynitride or pharmaceutically-acceptable salt thereof.